ArticleBrain pathology (Zurich, Switzerland)2000
Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains.
Article in Brain pathology (Zurich, Switzerland), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review.BMC veterinary research · 2013Pooled it
- Modeling pathogenic B cell function in experimental autoimmune encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Insights and challenges on animal models for progressive multiple sclerosis.Journal of neuroinflammation · 2026Review
- Active Induction of a Multiple Sclerosis-Like Disease in Common Laboratory Mouse Strains.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Anti-Glycolipid Antibody Examination in Five EAE Models and Theiler's Virus Model of Multiple Sclerosis: Detection of Anti-GM1, GM3, GM4, and Sulfatide Antibodies in Relapsing-Remitting EAE.International journal of molecular sciences · 2023Article
- Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2022Review
- Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function.Acta neuropathologica · 2022Review
- Recombinant myelin oligodendrocyte glycoprotein quality modifies evolution of experimental autoimmune encephalitis in macaques.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- A cell-based drug delivery platform for treating central nervous system inflammation.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.Neural regeneration research · 2020Review
- Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis.Frontiers in immunology · 2019Article
- Experimental Autoimmune Encephalomyelitis in Mice.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Th17-biased RORγt transgenic mice become susceptible to a viral model for multiple sclerosis.Brain, behavior, and immunity · 2015Article
- Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models.Inflammopharmacology · 2014Review
- Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice.International journal of molecular sciences · 2014Article
- Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?Pathophysiology : the official journal of the International Society for Pathophysiology · 2013Article
- Immunity and inflammation in neurodegenerative diseases.American journal of neurodegenerative disease · 2013Article
- Possible role of interleukin-17 in a prime/challenge model of multiple sclerosis.Journal of neurovirology · 2012Article
- Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines.Vaccine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) can be divided into 4 clinical forms: relapsing-remitting (RR), primary progressive (PP), secondary progressive (SP), and progressive relapsing (PR). Since PP-MS is notably different from the other forms of MS, both clinically and pathologically, the question arises whether PP-MS is immunologically similar to the other forms. The pathogenesis of the PP-MS remains unclear, partly due to a lack of highly relevant animal models. Using an encephalitogenic peptide from myelin oligodendrocyte glycoprotein (MOG)92-106, we have established animal models that mimic different forms of MS in 2 strains of H-2s mice, SJL/J and A.SW. We induced experimental allergic encephalomyelitis (EAE) using MOG92-106 in the presence or absence of supplemental Bordetella pertussis (BP). Although, SJL/J mice developed RR-EAE whether BP was given or not, A.SW mice developed PP-EAE without BP and SP-EAE with BP. Histologically, SJL/J mice developed mild demyelinating disease with T cell infiltration, while A.SW mice developed large areas of plaque-like demyelination with immunoglobulin deposition and neutrophil infiltration, but with minimal T cell infiltration. In A.SW mice without BP, high titer serum anti-MOG antibody was detected and the anti-MOG IgG2a/IgG1 ratio correlated with survival times of mice. We hypothesized that, in A.SW mice, a Th2 response favors production of myelinotoxic antibodies, leading to progressive forms with early death. Our new models indicate that a single encephalitogen could induce either RR-, PP-, or SP- forms of demyelinating disease in hosts with immunologically different humoral immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.